Lantheus (LNTH) Q4 FY25 earnings call

Lantheus is sharpening its strategic focus on radiodiagnostics, divesting its legacy SPECT business and pursuing value-maximizing alternatives for radiotherapeutic assets. The company anticipates multiple FDA approvals in 2026, setting the stage for accelerated revenue and earnings growth in 2027, despite an expected PYLARIFY net revenue decline in FY26. Management is prioritizing commercial execution and pipeline advancement while optimizing its cost structure to deliver on EPS targets.